A Study to Assess Cerebrospinal Fluid INflammatory Markers After Addition of Maraviroc to MONotherapy Darunavir/Ritonavir - The CINAMMON Study
PHASE4CompletedINTERVENTIONAL
Enrollment
19
Participants
Timeline
Start Date
November 30, 2012
Primary Completion Date
November 30, 2015
Study Completion Date
February 29, 2016
Conditions
HIV
Interventions
DRUG
maraviroc
Trial Locations (1)
SW10 9TH
St Stephen's AIDS Trust, London
All Listed Sponsors
lead
St Stephens Aids Trust
OTHER
NCT01680536 - A Study to Assess Cerebrospinal Fluid INflammatory Markers After Addition of Maraviroc to MONotherapy Darunavir/Ritonavir - The CINAMMON Study | Biotech Hunter | Biotech Hunter